Tag: sustained release excipients industry share

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Sustained Release Excipients Market Evolve in Terms of Growth and Size by 2029?

In the past few years, the market size for sustained release excipients has seen substantial growth. The market is projected to expand from $1.4 billion in 2024 to $1.51 billion in 2025, with an 8.1% compound annual growth rate (CAGR). This upward trend in the historical period can be credited to factors such as the rising demand for controlled drug release, the prevalent cases of chronic diseases, patient compliance and convenience, innovative strides in the pharmaceutical industry, and regulatory backing for extended-release formulations.

The market size of sustained release excipients is projected to significantly expand in the coming years, with an estimation of reaching $2.1 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.5%. The driving forces behind this anticipated growth during the forecast period may be the growing elderly population, increased attention towards personalized medication, patient adherence challenges, the rise of complex drug formulations, advancements in disease management, and the expansion of global healthcare. Key trends predicted within this time frame include a focus on patient-focused drug delivery, partnerships for formulation development, regulatory compliance and safety, worldwide extension of drug formulation technologies, and the impact of biopharmaceuticals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What factors are expected to fuel Sustained Release Excipients market growth in the coming years?

The sustained-release excipients market growth is anticipated to surge owing to the escalating prevalence of chronic and acute diseases. Chronic ailments, which last for an extended time, typically more than three months, and acute illnesses, characterized by rapid and usually severe but short-lived symptoms, are two categories that illnesses are classified into. The formulations of pharmaceutical products for both types of diseases extensively involve the use of sustained-release excipients. It enhances patient compliance, ensures uniform drug levels, minimizes side effects, and streamlines disease management, factors that augment the sales of sustained-release excipients. As reported by the World Health Organization (WHO), a health agency based in Switzerland, in September 2022, the most deaths from non-communicable diseases were due to cardiovascular diseases, amounting to 17.9 million people annually. This was followed by chronic respiratory diseases (4.1 million), diabetes (2.0 million, inclusive of deaths from kidney disease caused by diabetes), and cancer (9.3 million). An August 2022 report published by the American College of Cardiology, a non-profit medical association based in the US, projected significant rises from 2025 to 2060 in all four major cardiovascular risk factors in the US. It anticipates diabetes witnessing the highest proportional rise, soaring by 39.3% to 55 million individuals. This will be closely followed by dyslipidemia (increasing by 27.6% to 126 million), hypertension (rising by 25.1% to 162 million), and obesity (escalating by 18.3% to 126 million). Moreover, considerable rises are predicted in stroke rates (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) right on their heels. Therefore, the burgeoning prevalence of chronic and acute diseases is projected to drive the growth of the sustained-release excipients market.

What Are The Key Findings From The Segmentation Analysis Of The Sustained Release Excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Trends Are Expected To Shape The Future Of The Sustained Release Excipients Market?

Innovations in product development are becoming a significant trend in the scar treatment market. Key market players are evolving skincare technology with the intention to boost treatment effectiveness, better patient outcomes, and offer non-invasive alternatives for those desiring scar diminution. The objective of this technology is to augment the efficiency of treatments, increase safety measures, and deliver ideal results for a range of skin worries. For example, Doctors Aesthetics Centre, a company based in India, introduced Picocare Majesty, an innovative laser skincare gadget, for the first time in South India in March 2023. This tool employs the latest picosecond technology to specifically address and manage diverse scar issues, encompassing acne scars, surgical scars, and pigmentation problems.

What Are The Most Active Companies In The Sustained Release Excipients Market Today?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Regional Markets Are Attracting The Most Investment In Sustained Release Excipients?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Sustained Release Excipients Market?

In recent times, the market size of sustained release excipients has expanded significantly. Its growth projection starts from $1.4 billion in 2024 and is supposed to reach $1.53 billion by 2025, growing at a compound annual growth rate (CAGR) of 9.1%. The growth witnessed during the historical period is reportedly due to heightened demand for controlled drug release, the prevalence of chronic diseases, patient adherence and ease of use, innovative strides in the pharmaceutical industry, as well as regulatory support for extended-release formulations.

What Growth Rate Is Forecasted for the Sustained Release Excipients Market by 2029?

In the coming years, the market for sustained release excipients is projected to experience robust growth, reaching a size of “$2.13 billion by 2029 with a compound annual growth rate (CAGR) of 8.8%. This growth within the forecast period is largely attributable to factors such as a growing elderly population, emphasis on personalized medicine, challenges linked to patient adherence, escalating intricate drug formulations, advancements in managing diseases, and the worldwide expansion of healthcare. The major trends anticipated during the forecast period involve patient-focused drug delivery, partnerships for developing formulations, compliance with regulations and safety, worldwide growth of drug formulation technologies, and the impact of biopharmaceuticals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

Which Key Companies Are Shaping the Future of the Sustained Release Excipients Market?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Which Factors Are Driving Demand in the Sustained Release Excipients Industry?

The rise in chronic and acute illnesses is anticipated to fuel the expansion of the sustained-release excipients market. Chronic and acute illnesses differ based on their duration and development, with the former lasting long periods, typically over three months, and the latter being severe but brief, only lasting a few hours to weeks. The broad application of sustained-release excipients to formulate drugs for these disease types has contributed to market growth. This is due to their ability to enhance patient compliance, maintain stable drug concentrations, lessen adverse effects, and optimize disease control. The World Health Organization reported in September 2022 for example that cardiovascular diseases, causing 17.9 million deaths annually, were the leading NCD killer, followed by chronic respiratory diseases (4.1 million), diabetes (2.0 million, which includes deaths from kidney disease caused by diabetes), and cancer (9.3 million). Moreover, a report from the American College of Cardiology in August 2022 projected that the main four cardiovascular risk factors would rise from 2025 to 2060 in the United States. The sharpest increase is predicted in diabetes, with a 39.3% hike to 55 million people, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Additionally, significant escalations in cardiovascular disease rates are expected for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) trailing closely. Consequently, the escalating occurrence of chronic and acute illnesses propels the advancement of the sustained-release excipients market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

How Is the Sustained Release Excipients Market Segmented by Several Divisions?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

What are the Emerging Market Trends Driving the Growth of the Sustained Release Excipients Industry?

The trend of product innovation is becoming increasingly prevalent in the sustained release excipients market. Key players in the market are focused on creating innovative products to solidify their market presence. For example, Nutriventia Limited, a pharmaceutical company located in India, rolled out a novel product called Prolanza in September 2022. This is a sustained-release ashwagandha ingredient (Withania somnifera) that provides long-lasting support for stress reduction. Thanks to its unique delivery system, Prolanza exhibits therapeutic benefits for an elongated period with just one daily dosage. The ashwagandha in Prolanza showed superior absorption rates and bioavailability, and a prolonged elimination half-life compared to the control substance, underlining its sustained-release properties. With ashwagandha known for its adaptogen capabilities and stress response reduction, Prolanza’s therapeutic effects are long-lasting and beneficial for overall health. Made from natural herbs, its efficacy has been clinically verified.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Regions Are Driving Growth in the Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10822

This Report Delivers Insight On:

1. How big is the sustained release excipients market, and how is it changing globally?

2. Who are the major companies in the sustained release excipients market, and how are they performing?

3. What are the key opportunities and risks in the sustained release excipients market right now?

4. Which products or customer segments are growing the most in the sustained release excipients market?

5. What factors are helping or slowing down the growth of the sustained release excipients market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the sustained release excipients industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Sustained Release Excipients Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, the market size for sustained release excipients has considerably expanded. It is projected to escalate from $1.4 billion in 2024 to $1.53 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. This growth during the historic period can be ascribed to a surge in demand for regulated drug release, the prevalence of chronic diseases, patient adherence and convenience, innovative measures in the pharmaceutical industry, and regulatory backing for extended-release formulations.

The market size of sustained release excipients is projected to experience a significant expansion in the coming years. The expected value is around “$2.13 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%. The anticipated growth during the forecast period is due to factors such as the increasing elderly population, an emphasis on personalized medication, issues with patient adherence, the emergence of complex drug formulations, advancements in disease management, and the expansion of global healthcare. Major emerging trends during this period include a focus on patient-centric drug delivery, partnerships for formulation development, adherence to regulatory compliance and safety, worldwide expansion of drug formulation technologies, and the impact of biopharmaceuticals.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What External and Internal Drivers Are Contributing to the Growth of theSustained Release Excipients Market?

The growth of the sustained-release excipients market is forecasted to be driven by the rising prevalence of both chronic and acute illnesses. These two categories are used to define illnesses based on their progression and duration. Chronic illnesses are those medical conditions enduring over a lengthy period, usually more than three months. On the other hand, acute illnesses present rapidly developing, often intense symptoms, but are short in duration, lasting from hours to days or weeks. Sustained-release excipients, used to manufacture drugs for both chronic and acute illnesses, enhance patient compliance, maintain steady drug levels, mitigate side effects and improve disease management. These benefits contribute to a boost in the sales of sustained-release excipients. As per the World Health Organization (WHO) in September 2022, 17.9 million annual NCD deaths were due to cardiovascular diseases, followed by chronic respiratory illnesses (4.1 million), diabetes related fatalities including renal disease (2.0 million), and cancer (9.3 million). Moreover, in August 2022, a report by the American College of Cardiology projected a nationwide increase in all four principal cardiovascular risk factors from 2025 to 2060. Diabetes is predicted to see the most significant rise – a 39.3% increase to 55 million, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Substantial rises are also expected in cardiovascular disease rates for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) trailings closely. Therefore, the escalating prevalence of chronic and acute health issues propels the growth of the sustained-release excipients market.

What Segment Types Define the Sustained Release Excipients Market Structure?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Sustained Release Excipients Market?

Product development remains a dominating trend within the sustained release excipients market, with leading corporations innovating their offerings to solidify their market presence. For instance, Nutriventia Limited, a pharmaceutical organization hailing from India, introduced Prolanza, a sustained-release variant of the ashwagandha ingredient (Withania somnifera) in September 2022. This avant-garde root-only extract of Ashwagandha extends constant support in lowering stress. Thanks to its unique release system, Prolanza delivers its healing benefits throughout an extended timeframe with a single daily dosage. As compared to a control component, Prolanza showed enhanced relative intake, better bioavailability, and an extended elimination half-life, proving its sustained-release nature. The health benefits of Prolanza are amplified due to the primary usage of ashwagandha, which is to adapt and reduce stress responses. Made from all-natural herbs and clinically verified to deliver results, the therapeutic effects of Prolanza can be experienced for a longer duration.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

What Is the Definition of the Sustained Release Excipients Market?

Sustained-release excipients refer to pharmaceutical ingredients or additives used in the formulation of drug delivery systems designed to achieve controlled or sustained release of active pharmaceutical ingredients (APIs) over an extended period of time. These excipients play a crucial role in controlling the release rate and duration of drug action, thereby optimizing therapeutic efficacy and patient compliance.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10822

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theSustained Release Excipients Market?

As chronic and acute illnesses become increasingly prevalent, the sustained-release excipients market is expected to witness significant growth. Chronic illnesses are medical conditions that endure for a prolonged period, usually three months or longer, while acute diseases are identified by a swift onset of severe but short-lived symptoms. These conditions may develop abruptly and are normally short-term, lasting anywhere from several hours to a few days or weeks. Sustained-release excipients have a wide range of applications in the pharmaceutical product formulation for both types of diseases. This is because they enhance patient compliance, maintain stable drug levels, minimize side effects, and improve disease management, thus driving the sales of sustained-release excipients. For example, cardiovascular diseases recorded the highest number of NCD deaths as per the World Health Organization (WHO), a Switzerland-based specialized health agency, in September 2022, affecting approximately 17.9 million people annually. This was closely followed by deaths from chronic respiratory diseases (4.1 million), diabetes (2.0 million), and cancer (9.3 million). Furthermore, a report published by the American College of Cardiology in August 2022 predicted increased prevalence of all four major cardiovascular risk factors across the US from 2025 to 2060. According to these projections, diabetes is expected to see the biggest surge, with a 39.3% increase to 55 million cases. This will be followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The report also predicted considerable increases in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), as well as ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) cases. As such, the rising prevalence of chronic and acute diseases is a significant driving factor for the growth of the sustained-release excipients market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

#What Long-Term Growth Rate is Expected for theSustained Release Excipients Market Between 2025 and 2034?

The market size of sustained release excipients has significantly expanded in the past few years. The market is projected to rise from $1.4 billion in 2024 to $1.53 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. Factors contributing to this growth during the previous years include elevated demand for controlled drug release, the widespread of chronic illnesses, compliance and convenience for patients, innovative developments in the pharmaceutical sector, and regulatory backing for extended-release formulations.

The market size for sustained release excipients is projected to experience significant growth in the coming years, climbing to $2.13 billion in 2029 with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period can be credited to factors such as the rising number of elderly individuals, the emphasis on individualized medicine, challenges concerning patient compliance, the increase in complex drug formulations, advancements in managing diseases, and the expansion of global healthcare. Noteworthy trends during this forecast period comprise patient-focused drug delivery, partnerships for the development of formulations, regulatory compliance and safety, global growth of drug formulation technologies, and the impact of biopharmaceuticals.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10822

Which Upcoming Market Trends and Innovations Are Set to Influence theSustained Release Excipients Market’s Path Forward?

The prevailing trend of product innovation is becoming increasingly popular within the sustained release excipients market. Major players in this market are focusing on the creation of inventive products to solidify their market standing. For example, Nutriventia Limited, a pharmaceutical company based in India, introduced Prolanza, an advanced ashwagandha ingredient (Withania somnifera) in September 2022, which is a sustained-release product. Prolanza, a pure ashwagandha root extract, provides enduring stress reduction support. It offers extended therapeutic effects with a unique release mechanism, requiring just a single daily dosage. Comparative studies showed that Prolanza ashwagandha had superior absorption, enhanced bioavailability, and extended elimination half-life than its control counterpart, indicating a sustained-release pattern. Given ashwagandha’s primary use of adapting to and reducing stress responses, Prolanza’s therapeutic effects promise to be more enduring and positively impact overall health. It’s a natural herb-based product clinically proven to be effective.

Who Are the Dominant Market Players Pushing the Boundaries of theSustained Release Excipients Market?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

#thebusinessresearchcompany #marketresearch #marketintelligence

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

What Regions Are Dominating the Sustained Release Excipients Market Growth?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Sustained Release Excipients Maret 2025, By The Business Research Company:

Animal Medicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Nanomedicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Pharmaceutical Excipients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the sustained release excipients market grown over the years?

In recent times, the market size for sustained release excipients has experienced substantial growth. The market, which was worth $1.4 billion in 2024, is expected to expand to $1.53 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. Factors like an upsurge in demand for controlled drug release, the prevalence of chronic diseases, patient adaptability and convenience, innovation in the pharmaceutical industry, and regulatory backing for extended-release formulations have contributed to the growth seen in the historic period.

What Is the forecasted market size and growth rate for the sustained release excipients market?

In the forthcoming years, the market size for sustained release excipients is predicted to witness robust expansion. The market is projected to soar to “$2.13 billion by 2029, registering a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this anticipated growth during the forecast period include the growing elderly population, increased emphasis on personalized medicine, patient adherence complications, the emergence of intricate drug formulas, advancements in treating diseases, and the worldwide development of healthcare. Noteworthy trends for the forecast period encompass patient-oriented drug delivery, partnerships for formulation development, regulatory adherence and safety, global proliferation of drug formulation methodologies, and the impact of biopharmaceuticals.

Get your sustained release excipients market report here!

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

What are the major factors driving growth in the sustained release excipients market?

The expanding occurrence of both chronic and acute illnesses is anticipated to drive the expansion of the sustained-release excipients market. The categorization of diseases into chronic and acute is primarily based on their duration and progression. Chronic ailments are long-standing health conditions persisting for a period typically exceeding three months. In contrast, acute ailments are marked by swift symptom onset, which may be severe but are generally short-lived, lasting from hours to weeks. Sustained-release excipients play a crucial role in the formation of pharmaceutical products for both varieties of diseases. They are effective in enhancing patient adherence, maintaining stable drug levels, reducing adverse effects, and bettering disease management, and hence, they contribute to the rising sales of sustained-release excipients. For example, as per the World Health Organization (WHO) in September 2022, the most non-communicable disease deaths were due to cardiovascular diseases, affecting 17.9 million people each year. This is followed by chronic respiratory illnesses (4.1 million), diabetes (2.0 million, including deaths due to kidney disease caused by diabetes), and cancer (9.3 million). Furthermore, according to an August 2022 report by the American College of Cardiology, all four major cardiovascular risk factors are projected to hike from 2025 to 2060 in the United States. These include a 39.3% increase in diabetes to 55 million people, followed by dyslipidemia (27.6% rise to 126 million), hypertension (25.1% rise to 162 million), and obesity (18.3% to 126 million). Also, substantial increases in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) rates are predicted, closely trailed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). The surge in both chronic and acute diseases, therefore, fuels the development of the sustained-release excipients market.

What key areas define the segmentation of the global sustained release excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What are the top market players propelling the growth of the sustained release excipients industry?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

What are the key trends shaping the future of the sustained release excipients market?

In the sustained release excipients market, the primary emerging trend is product innovation. Prolanza, a sustained-release ashwagandha ingredient, was launched by Nutriventia Limited, an Indian pharmaceutical company, in September 2022. The launch represents a move to solidify their market position by creating innovative products. This advanced Ashwagandha root-only extract offers ongoing stress relief. The unique release mechanism of Prolanza enables it to have long-lasting therapeutic effects from just one daily dose. Remarkably, Prolanza ashwagandha exhibited greater relative absorption, enhanced bioavailability, and a prolonged elimination half-life compared to the control component, suggestive of a sustained-release profile. Given that ashwagandha is widely used for its adaptive and stress reducing abilities, Prolanza’s therapeutic effects will have a lasting positive influence on health. Produced from natural herbs, its effectiveness has been clinically validated.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10822

What regions are dominating the sustained release excipients market growth?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Animal Medicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Nanomedicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Pharmaceutical Excipients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the sustained release excipients market grown over the years?

In recent times, the market size for sustained release excipients has experienced substantial growth. The market, which was worth $1.4 billion in 2024, is expected to expand to $1.53 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. Factors like an upsurge in demand for controlled drug release, the prevalence of chronic diseases, patient adaptability and convenience, innovation in the pharmaceutical industry, and regulatory backing for extended-release formulations have contributed to the growth seen in the historic period.

What Is the forecasted market size and growth rate for the sustained release excipients market?

In the forthcoming years, the market size for sustained release excipients is predicted to witness robust expansion. The market is projected to soar to “$2.13 billion by 2029, registering a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this anticipated growth during the forecast period include the growing elderly population, increased emphasis on personalized medicine, patient adherence complications, the emergence of intricate drug formulas, advancements in treating diseases, and the worldwide development of healthcare. Noteworthy trends for the forecast period encompass patient-oriented drug delivery, partnerships for formulation development, regulatory adherence and safety, global proliferation of drug formulation methodologies, and the impact of biopharmaceuticals.

Get your sustained release excipients market report here!

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

What are the major factors driving growth in the sustained release excipients market?

The expanding occurrence of both chronic and acute illnesses is anticipated to drive the expansion of the sustained-release excipients market. The categorization of diseases into chronic and acute is primarily based on their duration and progression. Chronic ailments are long-standing health conditions persisting for a period typically exceeding three months. In contrast, acute ailments are marked by swift symptom onset, which may be severe but are generally short-lived, lasting from hours to weeks. Sustained-release excipients play a crucial role in the formation of pharmaceutical products for both varieties of diseases. They are effective in enhancing patient adherence, maintaining stable drug levels, reducing adverse effects, and bettering disease management, and hence, they contribute to the rising sales of sustained-release excipients. For example, as per the World Health Organization (WHO) in September 2022, the most non-communicable disease deaths were due to cardiovascular diseases, affecting 17.9 million people each year. This is followed by chronic respiratory illnesses (4.1 million), diabetes (2.0 million, including deaths due to kidney disease caused by diabetes), and cancer (9.3 million). Furthermore, according to an August 2022 report by the American College of Cardiology, all four major cardiovascular risk factors are projected to hike from 2025 to 2060 in the United States. These include a 39.3% increase in diabetes to 55 million people, followed by dyslipidemia (27.6% rise to 126 million), hypertension (25.1% rise to 162 million), and obesity (18.3% to 126 million). Also, substantial increases in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) rates are predicted, closely trailed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). The surge in both chronic and acute diseases, therefore, fuels the development of the sustained-release excipients market.

What key areas define the segmentation of the global sustained release excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What are the top market players propelling the growth of the sustained release excipients industry?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

What are the key trends shaping the future of the sustained release excipients market?

In the sustained release excipients market, the primary emerging trend is product innovation. Prolanza, a sustained-release ashwagandha ingredient, was launched by Nutriventia Limited, an Indian pharmaceutical company, in September 2022. The launch represents a move to solidify their market position by creating innovative products. This advanced Ashwagandha root-only extract offers ongoing stress relief. The unique release mechanism of Prolanza enables it to have long-lasting therapeutic effects from just one daily dose. Remarkably, Prolanza ashwagandha exhibited greater relative absorption, enhanced bioavailability, and a prolonged elimination half-life compared to the control component, suggestive of a sustained-release profile. Given that ashwagandha is widely used for its adaptive and stress reducing abilities, Prolanza’s therapeutic effects will have a lasting positive influence on health. Produced from natural herbs, its effectiveness has been clinically validated.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10822

What regions are dominating the sustained release excipients market growth?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Animal Medicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Nanomedicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Pharmaceutical Excipients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: